- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00300755
Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)
A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Disease (GERD)
To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
-
London, Ontario, Canada, N6A 4G5
-
Ottawa, Ontario, Canada, K1H 8L1
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
-
Montreal, Quebec, Canada, H3T 1C5
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36604
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
-
-
California
-
Oakland, California, United States, 94609
-
Orange, California, United States, 92868
-
Sacramento, California, United States, 95819
-
San Diego, California, United States, 92103
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20010
-
-
Florida
-
Gainesville, Florida, United States, 32610
-
Jacksonville, Florida, United States, 32207
-
Miami, Florida, United States, 33101
-
Orlando, Florida, United States, 32806
-
Pensacola, Florida, United States, 32504
-
-
Illinois
-
Peoria, Illinois, United States, 61603
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
-
Louisville, Kentucky, United States, 40202
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
-
Boston, Massachusetts, United States, 02115
-
-
Michigan
-
Flint, Michigan, United States, 48503
-
Southfield, Michigan, United States, 48075
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
-
-
Nebraska
-
Omaha, Nebraska, United States, 68105
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
-
-
New Jersey
-
Egg Harbor, New Jersey, United States, 08234
-
Morristown, New Jersey, United States, 07962
-
-
New York
-
Buffalo, New York, United States, 14222
-
New York, New York, United States, 10032
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822-1320
-
Philadelphia, Pennsylvania, United States, 19104
-
-
Texas
-
Houston, Texas, United States, 77030
-
Temple, Texas, United States, 76508
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
-
Huntington, West Virginia, United States, 25701-3655
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to undergo endoscopy with required biopsy
- Ages 1 through 5 years
- Endoscopically confirmed GERD by positive endoscopic evidence of reflux related esophagitis or positive histologic evidence of esophagitis consistent with GERD Other inclusions apply.
Exclusion Criteria:
- History or presence of upper gastrointestinal anatomic or motor disorders
- Known current or active cow's milk allergy
- Malignancy
- Other exclusions apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 1
Low Dose Pantoprazole (Approximately 0.3 mg/kg) |
Pediatric spheroids administered once daily for 8 weeks. |
|
Active Comparator: 2
Medium Dose Pantoprazole (Approximately 0.6 mg/kg) |
Pediatric spheroids administered once daily for 8 weeks. |
|
Active Comparator: 3
High Dose Pantoprazole (Approximately 1.2 mg/kg) |
Pediatric spheroids administered once daily for 8 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, and Final Week
|
Weekly GERD symptom score (WGSS) is the sum of 5 selected individual weekly GERD mean frequency scores: vomiting/regurgitation, choking/gagging, refusal to eat, difficulty swallowing and abdominal/belly pain. Symptoms were assessed using a parent-administered questionnaire. The score for each individual symptom ranged from 0 (no symptoms) to 3 (highest frequency of symptoms), giving a WGSS range of 0-15. Change = score at week of assessment minus baseline score. Final Week was defined as the last 7 days of symptom scores collected during the treatment period. |
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, and Final Week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Individual Weekly Mean Frequency Score for Each Gastroesophageal Reflux Disease (GERD) Symptom Score From Baseline to Final Week
Time Frame: Baseline and 8 weeks
|
Selected symptoms of GERD were assessed using a parent-administered questionnaire. The score for each symptom ranged from 0 (no symptom) to 3 (highest frequency of symptom), The weekly mean score was the sum of daily scores that week, divided by the number of days with scores for that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period. |
Baseline and 8 weeks
|
|
Change in Individual Weekly Mean Score For Each Respiratory Symptom From Baseline
Time Frame: Baseline and 8 weeks
|
Individual respiratory symptoms weekly score was calculated as the average score / number of events for a patient in the corresponding week if the patient answered a question ≥3 times that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period. |
Baseline and 8 weeks
|
|
Number of Patients With "Healed" Erosive Esophagitis (EE) at End of Study
Time Frame: 8 weeks
|
Healed EE was defined as a modified Hetzel-Dent (HD) score <2 on endoscopy at end of study. HD is a standardized rating scale for grading esophageal damage and severity of gastroesophageal reflux disease (GERD). HD score ranges from 0 (normal mucosa) to 4 (deep peptic ulceration). |
8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3001B3-328
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.